ZUG, Switzerland — November 10, 2025 — Leads & Copy — Pharvaris (Nasdaq: PHVS) presented data from two oral presentations and six posters at the 2025 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI) in Orlando, Fla., from November 6-10, 2025. The presentations highlighted the long-term safety and sustained benefits of deucrictibant for hereditary angioedema (HAE) and clinical validation data of a kinin biomarker assay.
Berndt Modig, Chief Executive Officer of Pharvaris, expressed pride in the scientific community’s recognition of the importance of the late-stage confirmatory clinical data of deucrictibant and associated biomarker work.
Key presentation details include:
Data from the CHAPTER-1 open-label extension (OLE) study indicated a well-tolerated safety profile for deucrictibant over approximately 34 months, with an average of 92.4% attack reduction from the study baseline. Marc A. Riedl, M.D., M.S., presented these findings in an oral presentation titled “Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension.” The study reported that the mean attack rate was reduced from 2.18 attacks/month to 0.12 attacks/month in the OLE. The mean rates of “moderate and severe” attacks and attacks treated with rescue medication remained low (0.06 attacks/month, N=30).
Michael E. Manning, M.D., presented data from the CHAPTER-1 OLE in an oral presentation titled “Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1,” showing clinically meaningful improvements in disease control and health-related quality of life (HRQoL) for up to approximately 34 months with deucrictibant treatment.
Zhi-Yi Zhang, Ph.D., presented continued Phase 1 data supporting the once-daily applicability of deucrictibant extended-release tablet in an oral presentation titled “Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks,” including single-dose sustained (≥24 hours) therapeutic exposure during repeat dosing under both fasted and fed conditions.
Joshua S. Jacobs, M.D., presented data supporting deucrictibant’s single-dose durability in an oral presentation titled, “Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks.” Results from part A of the RAPIDe-2 long-term extension study, showed that ~85% of attacks treated with a single dose of deucrictibant immediate-release (IR) capsule achieved symptom resolution within 24 hours (RAPIDe-2).
John Anderson, M.D., presented the final results of Part A of the RAPIDe-2 extension study, consistent with the Phase 2 RAPIDe-1 clinical trial, confirming deucrictibant remained well-tolerated in an oral presentation titled, “Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results.” Deucrictibant treatment yielded clinically-differentiating efficacy findings, including a median time to onset of symptom relief of 1.1 hours, with 97.8% of attacks achieving this milestone in 12 hours, and a median time to complete resolution of 10.6 hours, with 89.2% of the attacks resolving at 24 hours being treated with a single dose.
John Anderson, M.D., also presented in an oral presentation titled, “Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results,” consistency was observed between outcomes after deucrictibant treatment of upper airway HAE attacks, including laryngeal attacks, and HAE attacks occurring in other locations in the final results from Part A of the RAPIDe-2 long-term extension study.
Mark D. Scarupa, M.D., presented in an oral presentation titled, “Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis,” following a propensity score matching analysis of deucrictibant IR capsule-treated attacks from the RAPIDe-2 Phase 2/3 long-term extension study and a cohort of standard-of-care-treated attacks in a mixed-methods, real-world observational study, deucrictibant-treated attacks demonstrated more favorable outcomes across most efficacy endpoints.
Evangelia Pardali, Ph.D., presented in an oral presentation titled, “Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema,” that Pharvaris has established an assay that can measure the levels of bradykinin and other kinin peptides in plasma to characterize people with bradykinin-mediated angioedema. The clinically validated kinin biomarker assay may become a key tool for identifying, studying, and managing BK-mediated pathologies, including angioedema.
Dr. Peng Lu, Chief Medical Officer of Pharvaris, mentioned the anticipation for the Phase 3 data readout of CHAPTER-3 in the second half of 2026, emphasizing the compelling data package for deucrictibant.
Anne Lesage, Ph.D., Chief Early Development Officer of Pharvaris, highlighted the potential for identifying further applications for deucrictibant using the kinin biomarker assay.
Maggie Beller, Executive Director, Head of Corporate and Investor Communications, can be contacted at maggie.beller@pharvaris.com.
Source: Pharvaris
